반응식
[NH2:1][C:2]1[S:6][C:5]([C:7]2[C:12]([F:13])=[CH:11][C:10]([C:14]([OH:17])([CH3:16])[CH3:15])=[CH:9][C:8]=2[F:18])=[N:4][C:3]=1[C:19]([NH2:21])=[O:20].Br[C:23]1[N:28]=[CH:27][C:26]([C:29]([OH:32])([CH3:31])[CH3:30])=[CH:25][CH:24]=1.CC(C1C=C(C(C)C)C(C2C=CC=CC=2P(C2CCCCC2)C2CCCCC2)=C(C(C)C)C=1)C.C(=O)([O-])[O-].[K+].[K+].C(O)(CC)(C)C>C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.[Pd].[Pd]>[F:13][C:12]1[CH:11]=[C:10]([C:14]([OH:17])([CH3:16])[CH3:15])[CH:9]=[C:8]([F:18])[C:7]=1[C:5]1[S:6][C:2]([NH:1][C:23]2[CH:24]=[CH:25][C:26]([C:29]([OH:32])([CH3:31])[CH3:30])=[CH:27][N:28]=2)=[C:3]([C:19]([NH2:21])=[O:20])[N:4]=1참가 물질
7
반응물 5
생성물 1
시약·촉매·용매 1
실험 절차
The title compound was prepared as described in Example 15, Step 7 using 5-amino-2-[2,6-difluoro-4-(1-hydroxy-1-methylethyl)phenyl]-1,3-thiazole-4-carboxamide (Example 15, Step 5) (42 mg, 0.13 mmol), 2-(6-bromopyridin-3-yl)propan-2-ol (for preparation, see WO 2004/050024 A2 Example 120 Step A) (29 mg, 0.13 mmol), Pd2(dba)3 (12 mg, 0.013 mmol), X-PHOS (32 mg, 0.067 mmol), potassium carbonate (19 mg, 0.13 mmol), and tert-amyl alcohol (0.27 ml) as starting materials. 1H NMR (500 MHz, d6-DMSO) δ 11.31 (s, 1H), 8.40 (d, 1H), 7.83 (dd, 1H), 7.65 (s, 1H), 7.48 (s, 1H), 7.32 (d, 2H), 7.20 (d, 1H), 5.38 (s, 1H), 5.13 (s, 1H), 1.44 (s, 6H), 1.43 (s, 6H). LRMS (APCI) calc'd for C21H23F2N4O3S [M+H]+ 449.1, found 449.0.
출처 및 근거
- ORD 기록
- ord-08a89075738440b984fd96eab72a37cf
- 출처 데이터셋
- uspto-grants-2012_10
- 특허 번호
- US08278335B2
연결된 노트
불러오는 중…